News | Prostate Cancer | December 09, 2016

Exact Imaging Receives FDA 510(k) Clearance for Its ExactVu Micro-Ultrasound System

New Disruptive Prostate Micro-Imaging and Biopsy System Approved for Commercial Release in the United States

Exact Imaging Receives FDA 510(k) Clearance for Its ExactVu Micro-Ultrasound System

Exact Imaging, a leader in high resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance of the prostate, announced it has received FDA 510(k) Clearance for its ExactVu micro-ultrasound system.

"This has been a great few weeks with the receipt of our 510(k) clearance and the announcement of our CE approval just two weeks ago," said Randy AuCoin, Exact Imaging's president and CEO. "These important regulatory approvals will allow our commercial team to start fulfilling the pent-up demand for the ExactVu micro-ultrasound system. The era of blind, unguided biopsies is coming to an end and urologists are searching for new tools that leverage break-through technologies, familiar workflows and allow them to benefit from improved imaging resolution to target their prostate biopsies. Our platform is such a solution — it images in real-time, it is located in the urologist's office, and it is ultrasound-based. Most important, it allows for the guidance of both systematic and targeted biopsies due to its exquisite resolution."

With resolution down to 70 microns — or 0.07 of a millimeter, the ExactVu high resolution system provides a 300 percent improvement in imaging resolution compared to the traditional standard-of-care urological ultrasound systems. Urologists now have a tool, designed around their workflow, to facilitate the detailed interrogation and visualization of suspicious regions and perform targeted prostate biopsies.

The ExactVu micro-ultrasound recently received CE marking enabling sales of the system in Europe.  Exact Imaging's European commercial operations are being set-up in its new European headquarters in Belgium.  With this 510(k) clearance, North American sales, clinical applications and technical support teams are being expanded to support the anticipated growth in US customers.

For more information: www.exactimaging.com

Related Content

Long-term Hormone Therapy Increases Mortality Risk for Low-PSA Men After Prostate Surgery
News | Prostate Cancer | September 16, 2019
Secondary analysis of a recent clinical trial that changed the standard of care for men with recurring prostate cancer...
Isoray to Spotlight Cesium-131 Advances at ASTRO Annual Meeting
News | Brachytherapy Systems | September 13, 2019
Isoray Inc. announced it will spotlight the growing cancer treatment applications of Cesium-131 brachytherapy at the...
The irregularly marginated left tumor mass that bulges the lateral capsule appears three times the volume on the multiplanar 3-D/4-D image reconstruction and shows complete extraprostatic extension

Figure 1. 2-D (top) vs 3-D (bottom). The irregularly marginated left tumor mass that bulges the lateral capsule appears three times the volume on the multiplanar 3-D/4-D image reconstruction and shows complete extraprostatic extension. Note: This anterolateral lesion is not clinically palpable.

Feature | Prostate Cancer | September 05, 2019 | By Robert Bard, M.D., DABR, FASLM
Extracapsular extension (ECE) is a major clinical indicator for brachytherapy or external beam treatment of prostate
Medical Imaging Rates Continue to Rise Despite Push to Reduce Their Use
News | Radiology Imaging | September 03, 2019
Despite a broad campaign among physician groups to reduce the amount of medical imaging, use rates of various scans...
Philips Debuts Cardiac Ultrasound and Enterprise Informatics Offerings at ESC 2019
News | Cardiac Imaging | August 30, 2019
Philips will showcase its latest cardiac care innovations at the European Society of Cardiology (ESC) Congress 2019,...
CIRS Launches Ultrasound Quality Assurance Software
Technology | Quality Assurance (QA) | August 30, 2019
August 30, 2019 — The CIRS Ultrasound...
Terason Partners With DiA Imaging Analysis for Point-of-care Cardiac Ultrasound AI
News | Cardiovascular Ultrasound | August 26, 2019
Ultrasound imaging company Terason has partnered with DiA Imaging Analysis, provider of artificial intelligence (AI)-...
Exo Imaging Raises $35 Million for Developmental Ultrasound Platform
News | Ultrasound Imaging | August 23, 2019
Exo Imaging Inc. announced a $35 million Series B financing round for its high-performance ultrasound platform based on...
Surging Demand for Image-guided, Stereotactic Radiation Therapy Driving Fiducial Marker Growth
News | Radiation Therapy | August 22, 2019
As fiducial markers gain traction in parallel to rising incidences of various cancer affecting lung, prostate, abdomen...
Videos | Treatment Planning | August 21, 2019
This is an example of the Mirada DLCExpert deep learning software that automatically identifies organs, segments and